Anticancer therapy targeting the erbB family of receptor tyrosine kinases.
about
HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignanciesAnti-HER2 vaccines: new prospects for breast cancer therapyTargeting the EGFR signaling pathway in cancer therapy.Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer.Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients.Targeting the epidermal growth factor receptor in colorectal cancer: advances and controversies.Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease.Dual blockade of EGFR and ERK1/2 phosphorylation potentiates growth inhibition of breast cancer cells.Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment.Targeted therapies in the management of metastatic bladder cancerAnti-epidermal growth factor receptor strategies for advanced breast cancer.EGFR(s) in aging and carcinogenesis of the gastrointestinal tract.Histo-proteomic profiling of formalin-fixed, paraffin-embedded tissue.Cardiotoxicity associated with targeted cancer therapies.Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers.Lack of HER-2 gene amplification in non-Hodgkin lymphoma using chromogenic in situ hybridisation test.Trans-10,cis-12, not cis-9,trans-11, conjugated linoleic acid decreases ErbB3 expression in HT-29 human colon cancer cells.Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms.Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death.Her2 Ile655Val polymorphism and its association with breast cancer risk: an updated meta-analysis of case-control studies.Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations.Emerging drugs for ovarian cancer
P2860
Q26822730-B188DE6F-7145-4963-A0DA-ADDF1B24FAD1Q34105959-07FCD40D-5845-408A-B1C7-0E8B3BC72020Q34246558-9703DADF-FD87-4A49-9030-029CEEFDA8ABQ34659512-A36B1E96-3108-433F-99AA-DDB2E944552AQ34963574-EC75E71F-980F-4C7C-8636-DD0B559037ADQ36465260-0C345F80-8380-474A-A475-5F0A08FE1A2FQ36468876-586319B6-AAE4-4F45-8F5B-B6BE85FE94B2Q36615272-40EEA969-88A4-4C41-8CCB-B7E9C444CAE5Q36626059-A42D72E5-0B6D-4910-9D0F-ADA073764327Q36648369-F0DA2132-8706-4925-9EFE-0FB6D26F5CF5Q37290448-BA47FD9A-DFAF-4049-AFC6-8B5D92A6AB0BQ37293327-1BF87CC7-6BB7-4C53-8331-5141E03EFD74Q37552436-FAA20B65-2AA7-4E4C-A187-96CA10BF497BQ37727189-D7424679-5409-4D8D-B8B2-119E9F77F5E0Q38819670-903C59BC-1EBA-4D28-927C-D2FB27B3CF1EQ38867798-8A4DB8B6-297F-440F-BD06-49FAB741DB1CQ39978523-12ACB01A-9D51-457E-9D48-30052F3435A0Q43088457-A5A0DE2C-413F-4423-8180-D928212F6398Q47130146-A1F16ABC-C3FC-4515-A3D1-492D8244FA62Q49581426-6AABF9FE-E5AF-4DF3-BA88-9801279693F3Q54111164-8432A442-C141-44C6-9EE7-7E430047F972Q54601144-3D46A1F1-60E5-4211-86C4-5EAE2EEB127FQ57903790-BA8C210A-5139-49F4-8D97-8BEF6D25E702
P2860
Anticancer therapy targeting the erbB family of receptor tyrosine kinases.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Anticancer therapy targeting the erbB family of receptor tyrosine kinases.
@ast
Anticancer therapy targeting the erbB family of receptor tyrosine kinases.
@en
Anticancer therapy targeting the erbB family of receptor tyrosine kinases.
@nl
type
label
Anticancer therapy targeting the erbB family of receptor tyrosine kinases.
@ast
Anticancer therapy targeting the erbB family of receptor tyrosine kinases.
@en
Anticancer therapy targeting the erbB family of receptor tyrosine kinases.
@nl
prefLabel
Anticancer therapy targeting the erbB family of receptor tyrosine kinases.
@ast
Anticancer therapy targeting the erbB family of receptor tyrosine kinases.
@en
Anticancer therapy targeting the erbB family of receptor tyrosine kinases.
@nl
P1433
P1476
Anticancer therapy targeting the erbB family of receptor tyrosine kinases.
@en
P2093
W J Slichenmyer
P356
10.1016/S0093-7754(01)90284-2
P433
5 Suppl 16
P577
2001-10-01T00:00:00Z